Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: A mechanistic study using heart rate variability as a pharmacodynamic measure

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 236-239

  Chappell, Jill C ^a   Kovacs, Richard ^b,c   Haber, Harry ^d   Wright, Ryan ^a   Mitchell, Malcolm I ^a   Detke, Michael ^b,e   Pangallo, Beth ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Statprobe   (United States)

^e MedAvante Inc   (United States)

Author keywords

duloxetine; escitalopram; heart rate variability; norepinephrine; standard deviation of normal R R intervals

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADRENERGIC UPTAKE INHIBITORS; AGED; CITALOPRAM; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SINGLE-BLIND METHOD; THIOPHENES;

EID: 84874934620     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828567b6     Document Type: Article

References (23)

1. Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999;21(2 suppl):91SY98S.
2. Müller N, Schennach R, Riedel M, et al. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother. 2008;8:527-536. (Pubitemid 351551006)
3. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25: 871-880. (Pubitemid 34031892)
4. Trivedi MH, Desaiah D, Ossanna MJ, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008;23:161-169. (Pubitemid 351535907)
5. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl). 2006;185:395-399.
6. Hamaad A, Lip GY, MacFadyen RJ. Heart rate variability estimates of autonomic tone: relationship to mapping pathological and procedural stress responses in coronary disease. Ann Med. 2004;36:448-461. (Pubitemid 39331416)
7. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996;17:354-381.
8. Lobo E, Ernest CS, Detke M, et al. Pharmacokinetic/pharmacodynamic modeling of inhibition of serotonin and norepinephrine uptake by duloxetine and escitalopram in healthy subjects. Clin Pharmacol Ther. 2009;85(suppl 1S):S26. abstract
9. Umetani K, Singer DH, McCraty R, et al. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998;31:593-601. (Pubitemid 28144127)
10. Bigger JT Jr, Fleiss JL, Steinman RC, et al. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol. 1992;69:891-898.
11. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996; 67:588-597. (Pubitemid 26382973)
12. Lomb NR. Least-squares frequency analysis of unequally spaced data. Astrophysics and Space Science. 1976;39:447-462.
13. Berntson GG, Bigger JT Jr, Eckberg DL, et al. Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology. 1997; 34:623-648. (Pubitemid 27514918)
14. Udupa K, Sathyaprabha TN, Thirthalli J, et al. Alteration of cardiac autonomic functions in patients with major depression: a study using heart rate variability measures. J Affect Disord. 2007;100:137-141. (Pubitemid 46824143)
15. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol. 2002;12:461-475.
16. Kemp AH, Quintana DS, Gray MA, et al. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67:1067-1074.
17. Davidson J, Watkins L, Owens M, et al. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol. 2005;25:480-484. (Pubitemid 41368373)
18. Baumert M, Lambert GW, Dawood T, et al. Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Am J Physiol Heart Circ Physiol. 2009;297:H674YH679.
19. Tulppo M, Huikuri HV. Origin and significance of heart rate variability. J Am Coll Cardiol. 2004;43:2278-2280. (Pubitemid 38757598)
20. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30:437-455. (Pubitemid 46740340)
21. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007;23:1303-1318. (Pubitemid 46998440)
22. Moriya T, Fukushima T, Shimazoe T, et al. Chronic administration of methamphetamine does not affect the suprachiasmatic nucleus-operated circadian pacemaker in rats. Neurosci Lett. 1996;208:129-132. (Pubitemid 26128122)
23. Zuanetti G, Latini R, Neilson JM, et al. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol. 1991;17:604-612.